Bristol-Myers, Infinity Pharma To Evaluate Opdivo In Combination With IPI-549

Bristol-Myers Squibb Co. (BMY) and Infinity Pharmaceuticals, Inc. (INFI) on Monday announced a clinical trial collaboration to evaluate Bristol-Myers Squibb's Opdivo in combination with Infinity's IPI-549 in patients with advanced urothelial cancer.

from RTT - Biotech https://ift.tt/2DmURyi
via IFTTT